The Sichuan Provincial Bioinformatics Society (BISSC) is dedicated to serving the large health industry and people's livelihoods, integrating clinical medicine, cutting-edge medical informatics, artificial intelligence, and big data from multiple disciplines. The society gathers resources and interdisciplinary talents to achieve multi-party cooperation and development, building a bridge for communication and cooperation between society members, government, and enterprises, and promoting multi-party exchanges.

   In recent years, many Chinese new drug R&D companies have chosen to conduct overseas clinical trials of new drugs. Many pharmaceutical companies, including BeiGene, Alphamab Oncology, CStone Pharmaceuticals, Hengrui Medicine, and Betta Pharmaceuticals, have successively launched clinical trials overseas, with Australia being one of the popular destination choices. Australia's strong and flexible healthcare system and regulatory mechanism, a well-developed health ecosystem, an attractive investment environment, and strong policy support make its health ecosystem stand out; first-class medical research infrastructure and a multi-ethnic population structure give Australia unique advantages in the field of clinical trials.

   To better meet the needs of multi-center clinical trial paths and overseas strategy of Chinese innovative pharmaceutical companies, the Australian Clinical Trial Service Enterprise Group will visit Beijing and Chengdu on May 20 and 22, 2024, to hold offline exchange meetings with Chinese innovative drugs and biotechnology companies. They will discuss clinical R&D during the process of going overseas, exchange information on overseas policies and environmental status, share practical experience and insights, and explore future opportunities and development prospects.

   The Australian Trade and Investment Commission (Austrade)'s Greater China Region Head of Healthcare and Technology, Ms. Dai Han, will also attend the exchange meeting. She will share insights into the advantages of Australia's biotechnology industry and clinical trial services from the perspectives of government strategic planning, policy support, and industry ecology. This event is supported by the Beijing Zhongguancun Life Science Park, Chengdu Frontier Medical Center, and Sichuan Provincial Bioinformatics Society.

   Chinese innovative pharmaceutical companies and biotechnology company decision-makers are invited to attend the exchange meeting to discuss the future of Sino-Australian cooperation.

Beijing Station

(May 20, 2024, Monday)

Event Time: 14:00-17:30

Event Location: Zhongguancun Life Science Park International Conference Center

Address: Building 3, No. 20 Life Science Park Road, Changping District, Beijing

Registration Contact: Tang Kai

Email:colin.tang@austrade.gov.au;

Phone: +86 138 1067 6087

Registration Deadline: May 15, 2024 (Wednesday)

Chengdu Station

(May 22, 2024, Wednesday)

Event Time: 14:00-17:30

Event Location: Chengdu Frontier Medical Center, 2nd Floor, Paris Roadshow Hall, Building E1

Address: No. 366 Hemin Street, High-tech Zone, Chengdu

Registration Contact: Wang Ming

Email:ming.wang@austrade.gov.au;

Phone: +86 138 8098 4748

Registration Deadline: May 17, 2024 (Friday)

Note: Registration for the event requires manual review and approval

Introduction to Participating Australian Companies

(Sorted by the alphabetical order of the company's English name)

Agilex Biolabs (Only attending Chengdu station)

Company Website:www.agilexbiolabs.com

Company Profile: Agilex Biolabs is a leading bioanalytical and toxicology laboratory in Australia in terms of both scale and technology. Agilex Biolabs has a 28-year history in the bioanalytical industry, follows international research standards, has rich project experience, and is composed of more than 200 well-trained personnel from the United States, the United Kingdom, Australia, India, and China. The Australian-based team provides comprehensive support for sponsors' drug projects from pre-clinical research to phase I-IV clinical trials.

Chengdu Station

(May 22, 2024, Wednesday)

Event Time: 14:00-17:30

Event Location: Chengdu Frontier Medical Center
2nd Floor, Paris Roadshow Hall, Building E1

Address: No. 366 Hemin Street, High-tech Zone, Chengdu

Images

Registration Contact: Wang Ming

📧 ming.wang@austrade.gov.au;

📱 +86 138 8098 4748

Registration Deadline: May 17, 2024 (Friday)

Note: Registration for the event requires manual review and approval.

Introduction to Participating Australian Companies

(In alphabetical order by the company's English name)

Agilex Biolabs

(Only attending Chengdu station)

Company Website:www.agilexbiolabs.com

Company Profile: Agilex Biolabs is a leading bioanalytical and toxicology laboratory in Australia in terms of both scale and technology. With a 28-year history in the bioanalytical industry, Agilex Biolabs follows international research standards and has rich project experience. A team of over 200 well-trained personnel from the United States, the United Kingdom, Australia, India, and China provides comprehensive support for sponsors' drug projects from pre-clinical research to phase I-IV clinical trials.

Images

Services Network

Agilex Biolabs is an important member of the Healius network. Healius, established in 1994, is Australia's largest general practice medical center and the second-largest pathology provider, with nearly 2000 collection centers and the second-largest chain of imaging hospitals across Australia.

Cooperation Intention

Over the past 28 years, Agilex Biolabs has closely cooperated with sponsors from the United States, the Asia-Pacific region, and Europe. It has formulated specific clinical plans for each project, providing reliable and complete toxicological research, clinical bioanalysis, and biomarker data to ensure compliance with regulatory requirements, accelerating hundreds of non-clinical and clinical trials worldwide. Several projects from Chinese sponsors have already applied for the U.S. NDA new drug market application. Agilex Biolabs welcomes inquiries from pharmaceutical and biotechnology companies with global clinical needs.

AUGRANTS

Company Website:https://augrants.com.au

Company Profile: AUGRANTS is a consulting firm specializing in assisting Australian companies to apply for various government grants for long-term development. The company has successfully applied for R&D grants for many pharmaceutical companies conducting early clinical trials in Australia. This grant is a tax offset subsidy introduced by the Australian government to encourage companies to strengthen R&D and innovation activities, applicable to the costs incurred in clinical trials in Australia. It can provide up to 43.5% cash back for eligible R&D expenditure. AUGRANTS has experience in end-to-end services for many Australian clinical trial companies and can plan the entire R&D tax rebate process for companies in advance.

George Clinical

Company Website:https://www.georgeclinical.com/
https://georgeclinical.cn/

WeChat Public Account QR Code: [Image]

Company Profile: George Clinical is a global leading CRO established in the Asia-Pacific region, driven by scientific expertise and excellent operations. Since its establishment in 1999, George Clinical has rapidly developed in the Asia-Pacific region and has continued to grow and strengthen operations globally. Currently, George Clinical has more than 500 experienced employees in 40 locations worldwide and can manage clinical trials in 70 regions across the Asia-Pacific, the United States, and Europe, providing comprehensive clinical trial services for biotechnology, medical devices, and diagnostics in all trial phases, registration, and post-marketing trials. George Clinical has accumulated rich project execution experience in therapeutic areas such as oncology, kidney, endocrinology, cardiovascular, respiratory, central nervous system, and medical devices, with a unique and extensive network of scientific experts.

Novotech

(Only attending Chengdu station)

Company Website:http://www.novotech-cro.com/

WeChat Public Account: [Image]

Company Profile: Novotech, established in 1997, is based in the Asia-Pacific region and faces the world as a professional biotechnology contract research organization (CRO).

Paratus Clinical

(Only attending Beijing station)

Company Website:www.paratusclinical.com

Company Profile: Paratus Clinical was established in 2015 to meet the growing demand of global pharmaceutical and biotechnology companies for efficient, economical, and high-quality clinical trials in Australia. As a private company, Paratus can quickly respond to customer needs and improve the delivery speed of trials.

PCI Pharma Services

Company Website:https://pci.com/

Company Profile: PCI is a world-leading CDMO company, providing a full range of end-to-end drug development, manufacturing, and packaging solutions to accelerate product launch and improve commercial success rates. Every year, PCI helps pharmaceutical companies successfully launch more than 90 products, accumulating over fifty years of experience in supply chain pharmaceutical services. PCI has 30 sites worldwide and is committed to working with customers to provide life-changing treatment solutions for patients.

Resolian

Company Website:www.resolian.com

Company Profile: Resilian is a global leading bioanalytical contract research organization (CRO), providing professional services in GxP and non-regulated bioanalysis, drug metabolism/pharmacokinetics (DMPK), and GMP CMC analysis and material science. Resilian is composed of former Alliance Pharma Inc, Drug Development Solutions Ltd, and Denali Medpharma laboratories, with a team of over 500 experts from the United States, the United Kingdom, Australia, and China, providing continuous and comprehensive support for the entire drug project of pharmaceutical and biotechnology companies. Resilian's professional solutions include small and large molecule LC-MS/MS bioanalysis, large molecule PK immunoassay, immunogenicity, biomarkers, cell-based assays, and drug metabolism. These solutions are provided through Resilian's dedicated global laboratory network, equipped with the latest technology and equipment, ready to meet customer needs for pre-clinical research and regional or global clinical projects at any time.

Taikun Pharmaceutical Technology Pty Ltd

(Only attending Beijing station)

Company Website:www.taikunpharma.com

Industry Information

Main Advantages of Australian Clinical Trials

Australia's healthcare system ranks ninth in the world and is first-class. Australia has a thriving clinical trial industry, contributing approximately 1.4 billion Australian dollars to the Australian economy each year. The industry conducts over 1,880 new clinical trials annually, employs more than 8,000 Australians, and has more than 95,000 participants in clinical trials each year.

The Australian "Therapeutic Goods Act" of 1989 stipulates that all clinical research conducted in the country must follow ICH-GCP regulations. The strict and efficient regulatory system ensures the quality and progress of Australia's early clinical research, making Australia a top mainstream base for clinical trials worldwide for decades. Its main regulatory body, the Therapeutic Goods Administration (TGA), has long been among the world's top drug regulatory agencies, closely related to the Australian government's emphasis on and practice in clinical trials.

Australia offers international cooperation opportunities for global pharmaceutical R&D institutions to carry out phase I to IV clinical trials as well as target development and manufacturing, and is listed as one of the most ideal places for conducting clinical trials. The competitive advantages of conducting clinical trials in Australia are mainly reflected in three aspects: high-quality research, fast speed, and cost-effectiveness.